In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.
COVID-19 and Cardiology Read more
ESC TV – Guidelines
ESC TV – Guidelines

News and opinions on the latest ESC Clinical Practice Guidelines.

Watch now
 

Cancer treatments & cardiovascular toxicity 2016 (Position Paper)

This document reviews the different steps in cardiovascular monitoring and decision-makig before, during and after anticancer treatment with potential cardiovascular side-effects. This document aims to assist professionals involved in the treatment of patients with cancer and survivors by providing an expert consensus reading current standards of care for these individuals.

Cardio-Oncology
Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease


Guidelines version available to download

  • Full text
    Published in: 2016
    Reference Eur Heart J (2016) 37 (36): 2768-2801- doi:10.1093/eurheartj/ehw211
  • Pocket guidelines
    Published in: 2016
    Reference
  • Slide-set
    Published in: 2016
    Reference Online document
  • Summary card
    Published in: 2017
    Reference
Declarations of interest
Endorsed by cardiac societies
Albanian Society of Cardiology , Austrian Society of Cardiology , Belgian Society of Cardiology , Belorussian Scientific Society of Cardiologists , Association of Cardiologists of Bosnia & Herzegovina , British Cardiovascular Society , Bulgarian Society of Cardiology , Croatian Cardiac Society , Czech Society of Cardiology , Egyptian Society of Cardiology , Estonian Society of Cardiology , Finnish Cardiac Society , French Society of Cardiology , Georgian Society of Cardiology , German Cardiac Society , Hellenic Society of Cardiology , Hungarian Society of Cardiology , Israel Heart Society , Italian Federation of Cardiology , Kyrgyz Society of Cardiology , Latvian Society of Cardiology , Lithuanian Society of Cardiology , Luxembourg Society of Cardiology , Maltese Cardiac Society , Polish Cardiac Society , Portuguese Society of Cardiology , San Marino Society of Cardiology , Cardiology Society of Serbia , Slovak Society of Cardiology , Spanish Society of Cardiology , Swedish Society of Cardiology , Turkish Society of Cardiology

Table of contents: Full Text (ESC Clinical Practice Guidelines)

Table of Contents

Abbreviations and acronyms

Preamble

Introduction

Cardiovascular complications of anticancer therapy: pathophysiology and management

  • Myocardial dysfunction and heart failure
  • Coronary artery disease
  • Valvular disease
  • Arrhythmias
  • Arterial hypertension
  • Thromboembolic disease
  • Peripheral vascular disease and stroke
  • Pulmonary hypertension
  • Other cardiovascular complications of anticancer treatment
  • Cardiovascular complications of anticancer treatment in special populations

Strategies for prevention and attenuation of cardiovascular complications of anticancer therapy

  • Treatment options to prevent or recover from cancer therapy-induced myocardial dysfunction
  • Prevention of thromboembolic events
  • Strategies for attenuation of complications related to use of specific agents

Long-term surveillance programmes for cancer survivors

  • Myocardial dysfunction
  • Vascular disease
  • Valvular disease

Future perspectives and research directions
About the ESC
Press and Media
Information
Follow us

         

 Contact us

© 2020 European Society of Cardiology. All rights reserved.